抗癌化疗的免疫调节双重作用。
Dual role of immunomodulation by anticancer chemotherapy.
出版信息
Nat Med. 2013 Jan;19(1):20-2. doi: 10.1038/nm.3045.
Abstract
The anticancer efficacy of conventional chemotherapies seems to be due, in part, to augmentation of the host immune reactivity. However, a new study reveals that two common chemotherapeutic agents, gemcitabine and 5-fluorouracil, can also activate immune regulatory cells, which stimulates the emergence of protumorigenic cytokines via inflammasome pathways, limiting the antitumor efficacy of the drugs (pages 57–64).
摘要
常规化疗的抗癌疗效似乎部分归因于宿主免疫反应的增强。然而，一项新的研究表明，两种常见的化疗药物——吉西他滨和 5-氟尿嘧啶——也可以激活免疫调节细胞，这些细胞通过炎症小体途径刺激促肿瘤细胞因子的产生，从而限制了这些药物的抗肿瘤疗效（第 57-64 页）。
相似文献
1
Dual role of immunomodulation by anticancer chemotherapy.抗癌化疗的免疫调节双重作用。
Nat Med. 2013 Jan;19(1):20-2. doi: 10.1038/nm.3045.
2
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.化疗诱导髓系来源抑制细胞中组织蛋白酶 B 的释放激活 NLRP3 炎性小体并促进肿瘤生长。
Nat Med. 2013 Jan;19(1):57-64. doi: 10.1038/nm.2999. Epub 2012 Dec 2.
3
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].[化疗对免疫抑制的影响及新治疗靶点的发现]
Bull Cancer. 2014 Jun;101(6):605-7. doi: 10.1684/bdc.2014.1936.
4
Remote inflammatory and metabolic impact of acute injury.急性损伤的远程炎症和代谢影响
Crit Care Med. 2014 Jun;42(6):1539-40. doi: 10.1097/CCM.0000000000000292.
5
The NLRP3 inflammasome activation in human or mouse cells, sensitivity causes puzzle.人类或小鼠细胞中NLRP3炎性小体的激活及其敏感性令人困惑。
Protein Cell. 2013 Aug;4(8):565-8. doi: 10.1007/s13238-013-3905-0.
6
Purification and analysis of the interactions of caspase-1 and ASC for assembly of the inflammasome.胱天蛋白酶-1与凋亡相关斑点样蛋白相互作用的纯化及分析，用于炎性小体的组装。
Appl Biochem Biotechnol. 2015 Mar;175(6):2883-94. doi: 10.1007/s12010-014-1471-4. Epub 2015 Jan 8.
7
Caspase-4 is required for activation of inflammasomes.半胱氨酸天冬氨酸蛋白酶-4（Caspase-4）对于炎性体的激活是必需的。
J Immunol. 2012 Feb 15;188(4):1992-2000. doi: 10.4049/jimmunol.1101620. Epub 2012 Jan 13.
8
Inflammasomes in liver diseases.炎症小体与肝脏疾病。
J Hepatol. 2012 Sep;57(3):642-54. doi: 10.1016/j.jhep.2012.03.035. Epub 2012 May 23.
9
Negative regulation of NLRP3 inflammasome signaling.NLRP3 炎性体信号的负调控。
Protein Cell. 2013 Apr;4(4):251-8. doi: 10.1007/s13238-013-2128-8. Epub 2013 Mar 21.
10
Inflammasome activation leads to Caspase-1-dependent mitochondrial damage and block of mitophagy.炎性小体激活导致半胱天冬酶-1依赖性线粒体损伤和线粒体自噬受阻。
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15514-9. doi: 10.1073/pnas.1414859111. Epub 2014 Oct 13.
引用本文的文献
1
A syringeable immunotherapeutic hydrogel enhances T cell immunity via activation of STING pathway for advanced breast cancer postoperative therapy.一种可注射的免疫治疗水凝胶通过激活STING通路增强T细胞免疫，用于晚期乳腺癌术后治疗。
Front Immunol. 2025 Mar 19;16:1523436. doi: 10.3389/fimmu.2025.1523436. eCollection 2025.
2
Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer.紫杉醇纳米药物递送系统治疗三阴性乳腺癌的研究进展
Mater Today Bio. 2024 Nov 23;29:101358. doi: 10.1016/j.mtbio.2024.101358. eCollection 2024 Dec.
3
In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response.原位化学免疫治疗水凝胶引发免疫原性细胞死亡并引发有效的抗肿瘤免疫反应。
J Transl Med. 2024 Apr 9;22(1):341. doi: 10.1186/s12967-024-05102-0.
4
The role of host response to chemotherapy: resistance, metastasis and clinical implications.宿主对化疗的反应作用：耐药性、转移和临床意义。
Clin Exp Metastasis. 2024 Aug;41(4):495-507. doi: 10.1007/s10585-023-10243-5. Epub 2023 Nov 24.
5
Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.生物材料促进树突状细胞介导的癌症免疫治疗。
Adv Sci (Weinh). 2023 Jun;10(18):e2301339. doi: 10.1002/advs.202301339. Epub 2023 Apr 23.
6
A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy.一种用于联合免疫疗法和化疗的活性氧响应性协同递送系统。
Mater Today Bio. 2022 May 11;14:100284. doi: 10.1016/j.mtbio.2022.100284. eCollection 2022 Mar.
7
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.最佳犯罪搭档：解锁抗 EGFR 抗体西妥昔单抗联合自然杀伤细胞特许免疫治疗策略的潜力。
Front Immunol. 2021 Sep 7;12:737311. doi: 10.3389/fimmu.2021.737311. eCollection 2021.
8
Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses.原位凝胶化后进行局部鸡尾酒化疗免疫疗法，以触发强大的全身抗肿瘤免疫反应。
Sci Adv. 2020 Mar 4;6(10):eaaz4204. doi: 10.1126/sciadv.aaz4204. eCollection 2020 Mar.
9
Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.鲁比卡丁在慢性淋巴细胞白血病中的免疫调节作用。
Cancer Immunol Immunother. 2020 May;69(5):813-824. doi: 10.1007/s00262-020-02513-y. Epub 2020 Feb 13.
10
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.靶向上皮-间质转化与免疫系统之间的相互作用以实现有效的免疫治疗
Cancers (Basel). 2019 May 24;11(5):714. doi: 10.3390/cancers11050714.
本文引用的文献
1
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.化疗诱导髓系来源抑制细胞中组织蛋白酶 B 的释放激活 NLRP3 炎性小体并促进肿瘤生长。
Nat Med. 2013 Jan;19(1):57-64. doi: 10.1038/nm.2999. Epub 2012 Dec 2.
2
ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents.化疗免疫调节：抗肿瘤化学治疗药物的免疫调节作用。
Curr Med Chem. 2012;19(12):1792-803. doi: 10.2174/092986712800099785.
3
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.IL-17 产生的 γδ T 细胞对抗癌化疗疗效的贡献。
J Exp Med. 2011 Mar 14;208(3):491-503. doi: 10.1084/jem.20100269. Epub 2011 Mar 7.
4
Functional specialization of interleukin-17 family members.白细胞介素-17 家族成员的功能特化。
Immunity. 2011 Feb 25;34(2):149-62. doi: 10.1016/j.immuni.2011.02.012.
5
IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.白细胞介素-17 通过诱导肿瘤部位的肿瘤促进微环境和髓系来源的抑制性细胞来促进肿瘤的发展。
J Immunol. 2010 Mar 1;184(5):2281-8. doi: 10.4049/jimmunol.0902574. Epub 2010 Jan 29.
6
Protumor vs antitumor functions of IL-17.白细胞介素-17的促肿瘤与抗肿瘤功能
J Immunol. 2009 Oct 1;183(7):4169-75. doi: 10.4049/jimmunol.0901017.
7
Endogenous IL-17 contributes to reduced tumor growth and metastasis.内源性白细胞介素-17有助于抑制肿瘤生长和转移。
Blood. 2009 Jul 9;114(2):357-9. doi: 10.1182/blood-2008-09-177360. Epub 2009 Mar 16.
8
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.吉西他滨可选择性清除荷瘤动物脾脏中的Gr-1+/CD11b+髓源性抑制细胞，并增强抗肿瘤免疫活性。
Clin Cancer Res. 2005 Sep 15;11(18):6713-21. doi: 10.1158/1078-0432.CCR-05-0883.
9
Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.利用肿瘤疫苗与细胞毒性化疗的活性。
Cancer Res. 2005 Sep 15;65(18):8059-64. doi: 10.1158/0008-5472.CAN-05-1797.
10
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.低剂量环磷酰胺对CD4(+)25+调节性T细胞功能的抑制作用与增强免疫反应有关。
Blood. 2005 Apr 1;105(7):2862-8. doi: 10.1182/blood-2004-06-2410. Epub 2004 Dec 9.
Zotero 插件